Article
IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2018
Molenaar Remco J, Radivoyevitch Tomas, Nagata Yasunobu, Khurshed Mohammed, Przychodzen Bartolomiej, Makishima Hideki, Xu Mingjiang, Bleeker Fonnet E, Wilmink Johanna W, Carraway Hetty E, Mukherjee Sudipto, Sekeres Mikkael A, van Noorden Cornelis J F, Maciejewski Jaroslaw P
Abstract excerpt
Purpose: Somatic mutations in IDH1/2 occur in approximately 20% of patients with myeloid neoplasms, including acute myeloid leukemia (AML). IDH1/2MUT enzymes produce D-2-hydroxyglutarate (D2HG), which associates with increased DNA damage and improved responses to chemo/radiotherapy and PARP inhibitors in solid tumor cells. Whether this also holds true for IDH1/2MUT AML is not known.Experimental Design:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.